Prelude Capital Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Prelude Capital Management’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,974	Closed	-$411K	–	1583
2023 Q4	$411K	Buy	40,974 +24,647	+151%	+$112K	0.03%	603
2023 Q3	$47K	Buy	+16,327	New	+$59.7K	﹤0.01%	1049

Prelude Capital Management's GRCL Position: Q1 2024 in Review

Prelude Capital Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 40,974 shares — an estimated $411K sold.

Prelude Capital Management first reported a position in GRCL in Q3 2023 and held it in 2 quarters. The position peaked at $411K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Prelude Capital Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Prelude Capital Management sold 40,974 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $411K.
Prelude Capital Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023 and held it in 2 quarters.
Prelude Capital Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $411K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.